# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Francois Brisebois reiterates Durect (NASDAQ:DRRX) with a Outperform and maintains $5 price target.
HC Wainwright & Co. analyst Ed Arce reiterates Durect (NASDAQ:DRRX) with a Neutral.
Durect (NASDAQ:DRRX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.33) by 69....
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on rev...
- SEC Filing
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.